May 7, 2013
Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial
April 10, 2013
Aileron Therapeutics Presents New Preclinical Data on Stapled Peptide Inhibitor of Cancer Transcription Factor HIF-1α at AACR Annual Meeting
January 14, 2013
Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial
November 7, 2012
Aileron Therapeutics Presents New Data on Stapled Peptide Oncology Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Aileron and Stapled Peptides featured in SciBx collection "Macrocycles and Constrained Peptides."
Key insights on Stapled Peptides targeting p53 pathway in cancer published in ACS Chemical Biology letter titled, "Stapled Peptides with Improved Potency and Specificity That Activate p53."
April 6-10, 2013
American Association for Cancer Research (AACR) Annual Meeting 2013